Latest News & Features
Careers
Sapna Palla joins the firm in New York, bringing significant experience in complex life sciences and IP disputes to a growing practice. 12 November 2024
Americas
As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office. 7 November 2024
Americas
A US biopharma firm must pay the damages to Sandoz over a long-running dispute over lung therapy | New Jersey district judge had ordered the pair to “meet and confer” in a September judgment, but the parties couldn’t agree. 5 November 2024
Americas
The 47th US president will need to address the thorny issues of non-competes, patent rights and drug pricing. 5 November 2024
Americas
A jury in Delaware unanimously dismissed all allegations of misappropriation against Inhibrx, a Sanofi-owned biotech firm | Case stemmed from a previous arbitration involving the chief scientific officer of Inhibrx | Jury found no evidence supporting opponents claims, awarding the plaintiff $0 damages. 5 November 2024
Americas
New hire specialises in guiding life sciences and health tech clients through compliance issues | Work includes US regulations, including those enforced by the FDA, Drug Enforcement Administration and the Office of Inspector General. 31 October 2024
Europe
European Commission says fine “proportionate and necessary” after Teva spread misleading information about rival’s product | Teva says it is “deeply disappointed” and will appeal. 31 October 2024
Europe
The government’s autumn budget sends a positive signal but a more comprehensive approach is required to unlock the UK’s potential, says Graeme Moore of Mewburn Ellis. 31 October 2024
Americas
UK High Court judge unconvinced by Pfizer that uniQure’s patent is invalid | Companies in dispute over patents covering haemophilia B therapies in the US, Canada and UK 29 October 2024
Europe
Former head of life sciences at Gowling, joins Cooley’s London office as a partner | Brings expertise in cross-border licensing and collaboration deals in the pharmaceutical, biotech, and medical device sectors. 29 October 2024